In the past decade, ICB targeting PD-1, PD-L1, or CTLA-4 has proven effective against a variety of solid tumor malignancies as well as Hodgkin lymphoma, and there was optimism that ICB would be successful in GCB lymphomas as well. This evidence concerns the gene CTLA4 and lymphoma.